BIOADAPTIVES, INC.
For the period ended Dec 31, 2024. Filed Apr 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 15, 2025
BDPTStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Deficit
CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIT
| Additional | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Preferred stock · Series B Preferred stock · Series C Preferred stock · Series D Preferred stock · Common stock · paid-in · Subscription · Accumulated | |||||||||||||||||||||||
| Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount · capital · receivable · Deficit · Total | |||||||||||||||||||||||
| Balance, December 31, 2022 | 5,333 | $1 | - | $ | - | - | $ | - | - | $ | - | 1,683,704 | $168 | $6,100,009 | $ | - | $(7,551,679) | $(1,451,501) | |||||
| - | |||||||||||||||||||||||
| Series A preferred stock issued for license fee | 4,167 | - | - | - | - | - | - | - | - | - | 22,625 | - | - | 22,625 | |||||||||
| Series B preferred stock issued for license fee | - | - | 5,000 | 1 | - | - | - | - | - | - | 17,999 | - | - | 18,000 | |||||||||
| Series B preferred stock issued for settlement of debt - related party | - | - | 2,500 | - | - | - | - | - | - | - | 16,500 | - | - | 16,500 | |||||||||
| Common stock issued for cash | - | - | - | - | - | - | - | - | 1,333,328 | 133 | 177,967 | - | - | 178,100 | |||||||||
| Common stock issued for conversion of debt | - | - | - | - | - | - | - | - | 2,954,696 | 296 | 281,815 | - | - | 282,111 | |||||||||
| Net loss for the period | - | - | - | - | - | - | - | - | - | - | - | - | (712,466) | (712,466) | |||||||||
| Balance, December 31, 2023 | 9,500 | $1 | 7,500 | $1 | - | $ | - | - | $ | - | 5,971,728 | $597 | $6,616,915 | $ | - | $(8,264,145) | $(1,646,631) | ||||||
| Series A preferred stock issued for license fee | 1,667 | - | - | - | - | - | - | - | - | - | 1,500 | - | - | 1,500 | |||||||||
| Series B preferred stock issued for license fee | - | - | 1,667 | - | - | - | - | - | - | - | 3,000 | - | - | 3,000 | |||||||||
| Series B preferred stock issued for settlement of debt - related party | - | - | 500 | - | - | - | - | - | - | - | 1,500 | - | - | 1,500 | |||||||||
| Series C preferred stock issued for purchase of inventory | - | - | - | - | 1,000,000 | 100 | - | - | - | - | 59,900 | - | - | 60,000 | |||||||||
| Series D preferred stock issued for conversion of common stock | - | - | - | - | - | - | 50,000 | 5 | - | - | 299,995 | (5885) | - | 294,115 | |||||||||
| Series D preferred stock issued for compensation | - | - | - | - | - | - | 22,687 | 2 | - | - | 208,869 | - | - | 208,871 | |||||||||
| Common stock issued for conversion of debt | - | - | - | - | - | - | - | - | 2,239,794 | 225 | 202,419 | (5,885) | - | 202,643 | |||||||||
| Reverse split adjustment Debt Forgiveness | -- | -- | -- | -- | -- | -- | -- | -- | 04 | - | 310,245 | - | - | 310245 | |||||||||
| Net loss for the period | - | - | - | - | - | - | - | - | - | - | - | - | (899,161) | (899,161) | |||||||||
| Balance, December 31, 2024 | 11,167 | $1 | 9,667 | $1 | 1,000,000 | $100 | 72,687 | $7 | 8,215,426 | $8,221 | $7,704,343 | $(5,885) | $(9,163,306) | $(1,463,918) | |||||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.